Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.59 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.57 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.57 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.57 |
| ▸ | XDH | P47989 | 2/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 1/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7688477 | 0.87 | GRIA1 (0.75) | FGFR1FGFR2GRIA1GRIA2GRIA3 | |
| SCHEMBL14716577 | 0.79 | FGFR1 (0.56) | FGFR1FGFR2GRIA1GRIA2GRIA3 | |
| Biphenyl SCHEMBL27410122 | 0.75 | PNP (0.79) | FGFR1FGFR2GRIA1GRIA2GRIA3 | |
| SCHEMBL1286943 | 0.74 | FGFR1 (1.00) | FGFR1FGFR2XDHALDH1A1HPGD | |
| SCHEMBL4624285 | 0.74 | ALDH1A1 (0.57) | GRIA1GRIA2GRIA3GRIA4SLC2A1 | |
| SCHEMBL26362619 | 0.72 | ADORA2B (0.48) | XDHALDH1A1KDM4EGAAHPGD | |
| SCHEMBL8906319 | 0.72 | ALDH1A1 (0.59) | GRIA1GRIA2GRIA3GRIA4XDH | |
| SCHEMBL7688479 | 0.71 | ADORA2B (0.46) | FGFR1FGFR2GRIA1GRIA2GRIA3 | |
| SCHEMBL8039258 | 0.71 | FGFR1 (0.62) | FGFR1FGFR2XDHALDH1A1HPGD | |
| SCHEMBL5667616 | 0.70 | PNP (0.73) | FGFR1FGFR2GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102335164-B | Application of 5,6,7,4'-tetrahydroxy flavone and derivatives thereof in preparation of drugs for preventing and treating hyperuricemia and gout | KUNMING PHARMACEUTICAL CORP | 2014-07-30 | — | — | CN | disclosed |
| US-8680270-B2 | Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2086546-B1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS INC (US) | 2013-07-10 | — | — | EP | disclosed |
| CN-102335164-A | Application of 5,6,7,4'-tetrahydroxy flavone and derivatives thereof in preparation of drugs for preventing and treating hyperuricemia and gout | KUNMING PHARMACEUTICAL CORP | 2012-02-01 | — | — | CN | disclosed |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2086546-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | Viamet Pharmaceuticals, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008064311-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | NQO1, SOD1, MDH2 | FGFR1 3577/4885FGFR2 3656/4885GRIA1 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.